Stock Yards Bank & Trust Co. Has $515,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

Stock Yards Bank & Trust Co. cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 2.9% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,203 shares of the medical instruments supplier’s stock after selling 65 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Becton, Dickinson and Company were worth $515,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of BDX. Livelsberger Financial Advisory bought a new position in Becton, Dickinson and Company in the fourth quarter valued at about $27,000. OLD Point Trust & Financial Services N A bought a new position in Becton, Dickinson and Company in the fourth quarter valued at about $29,000. Scarborough Advisors LLC bought a new position in Becton, Dickinson and Company in the fourth quarter valued at about $32,000. Rise Advisors LLC bought a new position in Becton, Dickinson and Company in the first quarter valued at about $38,000. Finally, ICA Group Wealth Management LLC bought a new position in Becton, Dickinson and Company in the fourth quarter valued at about $42,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 1.2 %

Shares of BDX stock opened at $231.27 on Wednesday. The company has a market cap of $66.84 billion, a P/E ratio of 50.94, a PEG ratio of 1.91 and a beta of 0.42. The stock has a 50 day simple moving average of $235.07 and a two-hundred day simple moving average of $235.57. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. During the same period in the previous year, the company posted $2.96 earnings per share. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. Research analysts forecast that Becton, Dickinson and Company will post 13.1 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be paid a $0.95 dividend. The ex-dividend date is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.64%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Analyst Ratings Changes

Several research firms have commented on BDX. Stifel Nicolaus increased their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Raymond James lowered their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Evercore ISI lowered their price objective on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. The Goldman Sachs Group started coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 price objective for the company. Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $279.50.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.